King Pharmaceuticals Inc Stock Probability Of Bankruptcy
KING PHARMACEUTICALS INC fundamentals help investors to digest information that contributes to KING PHARMACEUTICALS's financial success or failures. It also enables traders to predict the movement of KING Stock. The fundamental analysis module provides a way to measure KING PHARMACEUTICALS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to KING PHARMACEUTICALS stock.
KING |
KING PHARMACEUTICALS INC Company chance of financial distress Analysis
KING PHARMACEUTICALS's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability_Of_Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current KING PHARMACEUTICALS Probability Of Bankruptcy | Over 100% |
Most of KING PHARMACEUTICALS's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, KING PHARMACEUTICALS INC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of KING PHARMACEUTICALS probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting KING PHARMACEUTICALS odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of KING PHARMACEUTICALS INC financial health.
Please note, there is a significant difference between KING PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine if KING PHARMACEUTICALS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, KING PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, KING PHARMACEUTICALS INC has a Probability Of Bankruptcy of 100%. This is much higher than that of the sector and significantly higher than that of the Pharmaceutical Products industry. The probability of bankruptcy for all United States stocks is notably lower than that of the firm.
KING Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses KING PHARMACEUTICALS's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of KING PHARMACEUTICALS could also be used in its relative valuation, which is a method of valuing KING PHARMACEUTICALS by comparing valuation metrics of similar companies.KING PHARMACEUTICALS is currently under evaluation in probability of bankruptcy category among related companies.
KING Fundamentals
| Return On Asset | 0.026 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 3.2 B | |||
| Shares Outstanding | 248.24 M | |||
| Price To Earning | 32.29 X | |||
| Price To Book | 1.29 X | |||
| Price To Sales | 1.72 X | |||
| Revenue | 1.78 B | |||
| Gross Profit | 1.15 B | |||
| EBITDA | 453.31 M | |||
| Net Income | 91.95 M | |||
| Cash And Equivalents | 545.31 M | |||
| Cash Per Share | 1.58 X | |||
| Total Debt | 428.23 M | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 2.27 X | |||
| Cash Flow From Operations | 430.73 M | |||
| Earnings Per Share | 0.34 X | |||
| Market Capitalization | 3.05 B | |||
| Total Asset | 3.33 B | |||
| Retained Earnings | 963.62 M | |||
| Working Capital | 632.95 M | |||
| Current Asset | 1.13 B | |||
| Current Liabilities | 496.9 M | |||
| Z Score | 4.2 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the KING PHARMACEUTICALS INC information on this page should be used as a complementary analysis to other KING PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in KING Stock
If you are still planning to invest in KING PHARMACEUTICALS INC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KING PHARMACEUTICALS's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |